Fresenius Medical Care AG commences an Equity Buyback Plan for 279,288,885 shares, representing 10% of its issued share capital, under the authorization approved on May 21, 2026.
Fresenius Medical Care AG & Co. KGAA (XTRA:FME) commences share repurchases on May 28, 2026, under the program mandated by the shareholders in the Annual Shareholders? Meeting held on May 21, 2026 . As per the mandate, the company is authorized to repurchase up to 279,288,885 shares, representing 10% of its issued share capital. If shares are purchased on the stock exchange, the share price paid by the company (not including incidental acquisition costs) must not be more than 10% or less than 20% of the market price for shares of the company of the same class determined by the opening auction in the Xetra trading system (or a comparable successor system) on the respective stock exchange trading day. If shares are acquired by way of a public tender offer or a public invitation to shareholders to submit an offer for sale, the offer price per share paid by the company (not including incidental acquisition costs) must not be more than 10% or less than 20% of the average trading price of shares of the same class determined by the closing auction in the Xetra trading system (or a comparable subsequent system) on the last stock exchange trading day before the publication of the public tender offer or public invitation to shareholders to submit an offer for sale by more than 10%. The repurchased shares may be redeemed without the redemption or its execution requiring any further resolution by the general meeting, the general partner is authorized to sell treasury shares also in other ways than a sale on the stock exchange or an offer to all shareholders, also by way of an invitation to submit an offer, provided that the shares are sold for cash at a price that does not significantly fall short of the stock market price of shares of the company that are subject to the same terms at the time of the sale, repurchased shares can be sold to third parties against contributions in kind, in particular in the context of the acquisition of companies, parts of companies, interests in companies or other assets (including receivables) and with regard to mergers, repurchase shares, repurchased shares may be awarded in lieu of the utilization of a conditional capital of the company to employees of the company and companies affiliated with the company, including members of the management of affiliated companies, and use them to service options or obligations to purchase shares of the company granted to employees of the company or companies affiliated with the company as well as to members of the management of affiliated companies, repurchased treasury shares can be used to service bonds carrying warrant and/or conversion rights or conversion obligations issued by the company. The program will be valid for a period of five years, until May 20, 2031. As of April 1, 2026, the company had 293,413,449 issued shares, including 14,124,564 treasury shares.
On May 26, 2026, the company announced a repurchase program. Under the plan, the company will repurchase up to 29,341,344 shares for ?1,000 million. The repurchased shares will be predominantly redeemed and, to a significantly lesser extent, may be used for allocations under incentive-based compensation plans. The program will commence from May 28, 2026 and will be valid till May 27, 2027. Under the first tranche of the program, the company will repurchase up to ?600 million worth of its shares. The first tranche will commence from May 28, 2026, and will be valid till December 15, 2026.
Fresenius Medical Care AG is the world's leading supplier of services and equipment for patients with kidney problems. Net sales break down by activity as follows:
- clinical care services (75.2%): operated, at the end of 2025, 3,601 institutions;
- manufacturing of dialyzers and related products (24.8%): hemo-dialysis and pediatric dialysis machines, etc. The group also offers therapies accompanied by care and treatment for dialysis patients.
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Fresenius Medical Care AG commences an Equity Buyback Plan for 279,288,885 shares, representing 10% of its issued share capital, under the authorization approved on May 21, 2026.